The decision has been taken by DMC following a pre-specified interim analysis from the Phase II and III clinical trial.
The partners said the trial did not meet the pre-specified futility criteria and further analysis of the benefit-risk of the vaccine candidate will be initiated.
S. aureus causes hospital-acquired infections and 50% of strains isolated in hospitals globally are resistant to antibiotics.